After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Clinical research agreements (CRAs) and developing a regulatory strategy—particularly in connection with the Food and Drug Administration ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...

Experts call for an EU-wide, mandatory Nutri-Score label to promote healthier diets and curb industry influence on ...

The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis ...

TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...

The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.